---
figid: PMC2964177__hyq08405
figtitle: Molecular crosstalk between the ER and ErbB1/ErbB2 cellular signaling pathways
  in endocrine-resistant ErbB2-positive breast cancer cells
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC2964177
filename: hyq08405.jpg
figlink: /pmc/articles/PMC2964177/figure/HYQ084F5/
number: F5
caption: Molecular crosstalk between the ER and ErbB1/ErbB2 cellular signaling pathways
  in endocrine-resistant ErbB2-positive breast cancer cells. Estrogen bound to the
  ER activates estrogen-regulated genes via a classical signaling pathway. ErbB1/ErbB2
  stimulation by growth factors results in activation of the PI3K/Akt and MAPK signaling
  pathways, leading to tumor cell growth. Long-term tamoxifen therapy may promote
  endocrine resistance via bidirectional crosstalk between the ER and growth factor
  receptor (i.e. IGF-1R or ErbB1/ErbB2) signaling pathway components. Bidirectional
  activation of these pathways promotes ER phosphorylation and ER target gene transcription
  as well as ErbB1/ErbB2/MAPK-mediated signaling and IGF-1R-mediated PI3K/Akt growth
  signaling pathways. Modulation of these pathways by combined use of lapatinib and
  anti-estrogen therapy (e.g. letrozole) may overcome endocrine resistance. CBP, cAMP
  response element binding protein (CREB)-binding protein; ER, estrogen receptor;
  ErbB1, human epidermal growth factor receptor 1; ErbB2, human epidermal growth factor
  receptor 2; mitogen-activated protein kinase; MEK, mitogen-activated protein kinase
  kinase; P, phosphate; p90RSK, p90 ribosomal S6 kinase; p160, p160 steroid receptor
  co-activator protein(s); PI3K, phosphatidylinositol-3-kinase; PTEN, phosphatase
  and tensin homologue deleted on chromosome 10; RAF, murine leukemia viral oncogene
  homologue 1; SOS, son-of-seven less guanine nucleotide exchange factor. Figure adapted
  from the publication by Johnston () (Fig. ) with permission from the American Association
  for Cancer Research.
papertitle: 'Management of ErbB2-positive Breast Cancer: Insights from Preclinical
  and Clinical Studies with Lapatinib.'
reftext: Charles Vogel, et al. Jpn J Clin Oncol. 2010 Nov;40(11):999-1013.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9661658
figid_alias: PMC2964177__F5
figtype: Figure
redirect_from: /figures/PMC2964177__F5
ndex: 07257d6b-ded1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2964177__hyq08405.html
  '@type': Dataset
  description: Molecular crosstalk between the ER and ErbB1/ErbB2 cellular signaling
    pathways in endocrine-resistant ErbB2-positive breast cancer cells. Estrogen bound
    to the ER activates estrogen-regulated genes via a classical signaling pathway.
    ErbB1/ErbB2 stimulation by growth factors results in activation of the PI3K/Akt
    and MAPK signaling pathways, leading to tumor cell growth. Long-term tamoxifen
    therapy may promote endocrine resistance via bidirectional crosstalk between the
    ER and growth factor receptor (i.e. IGF-1R or ErbB1/ErbB2) signaling pathway components.
    Bidirectional activation of these pathways promotes ER phosphorylation and ER
    target gene transcription as well as ErbB1/ErbB2/MAPK-mediated signaling and IGF-1R-mediated
    PI3K/Akt growth signaling pathways. Modulation of these pathways by combined use
    of lapatinib and anti-estrogen therapy (e.g. letrozole) may overcome endocrine
    resistance. CBP, cAMP response element binding protein (CREB)-binding protein;
    ER, estrogen receptor; ErbB1, human epidermal growth factor receptor 1; ErbB2,
    human epidermal growth factor receptor 2; mitogen-activated protein kinase; MEK,
    mitogen-activated protein kinase kinase; P, phosphate; p90RSK, p90 ribosomal S6
    kinase; p160, p160 steroid receptor co-activator protein(s); PI3K, phosphatidylinositol-3-kinase;
    PTEN, phosphatase and tensin homologue deleted on chromosome 10; RAF, murine leukemia
    viral oncogene homologue 1; SOS, son-of-seven less guanine nucleotide exchange
    factor. Figure adapted from the publication by Johnston () (Fig. ) with permission
    from the American Association for Cancer Research.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - MKP-4
  - p38b
  - rl
  - CBP
  - nej
  - eIF4E1
  - Dap160
  - MED14
  - pzg
  - IGF1R
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - EGFR
  - ERBB2
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - MSH6
  - MYBBP1A
  - PELP1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
